Aadi Bioscience, Inc. (AADI) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/06/23
Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual MeetingPRNewsWire • 11/17/22
Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/09/22
Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate UpdatePRNewsWire • 11/09/22
Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR SymposiumPRNewsWire • 10/27/22
Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] MutationPRNewsWire • 10/12/22
Aadi Bioscience Announces Participation in Upcoming September Investor ConferencesPRNewsWire • 09/01/22
Aadi Bioscience, Inc. (AADI) CEO Neil Desai on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/10/22
Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate UpdatePRNewsWire • 08/10/22
Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate CommunicationsGlobeNewsWire • 05/31/22
Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual MeetingGlobeNewsWire • 05/26/22
Aadi Bioscience to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/18/22
Aadi Bioscience, Inc. (AADI) CEO Neil Desai on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/12/22
UPDATE -- Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 05/12/22